Procore Technologiesの空売り状況は、投資家がProcore Technologiesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Procore Technologies (NYSE:PCOR) 株価情報, 空売り情報

Procore Technologies

Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.

Procore Technologies Inc

Grant Cardone is a successful real estate investor and author of "The 10X Rule." He regularly shares business advice but has been getting more political as speculation about him running for California's next governor continues to grow.
He recently <a href="https://x.com/GrantCardone/status/1909397453129785674">posted on X</a> about what it takes to make a deal. The post came under the context of Trump's tariffs, but business owners can also benefit from Cardone's insights.
"It takes 4 things to make a deal," Cardone explained in the post.&nbsp;
If you want to make a business deal or close on a property, you will need these components.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
<h2 class="wp-block-heading">Decision Makers At The Table</h2>
Cardone starts off by mentioning decision makers. Sometimes, it's hard to make the deal because the decision makers are insulated by people who do not have the authority to make key decisions.
When you are pursuing an opportunity or an investment, you have to pinpoint the decision makers. You can find some decision makers based on an individual's occupation at a company. Other decision makers are accessible CEOs and founders.
<h2 class="wp-block-heading">Willingness &amp; Desire</h2>
Both parties must be willing to meet and desire a positive outcome. Dealmaking sometimes involves giving up on some of your preferences in favor of meeting somewhere in the middle. If a party isn't willing to budge, it can become more difficult to make a deal.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
You can approach a deal fully eager to reach an agreement. If the other party isn't interested, you can explain some of the benefits of working together or reaching a mutually beneficial solution. Even if the other party isn't willing, you can use the other two parts of dealmaking to move the conversation in your favor.
<h2 class="wp-block-heading">Urgency&nbsp;</h2>
Urgency inspires action, and Parkinson's Law shows this phenomenon in full effect. According to this law, we do our best work right before the deadline. It's easy to push off work if the deadline is far away, but adding urgency to a deal can speed up the conclusion.
Instead of letting negotiations drag on for months, you can introduce urgency by saying that you would like to make a deal by the end of the day. The shortened time frame allows Parkinson's Law to work in your favor. While adding urgency doesn't guarantee that you will make a deal, it can work in your favor.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Leverage</h2>
Cardone mentions leverage as the final thing you need to make a deal. When it comes to tariffs, Cardone said that leverage is Trump's greatest strength.
"Trump knows America only has one of the four points: leverage. Until decision makers have willingness, desire, and urgency to get a deal, there will not be a deal," he explained in the X post.&nbsp;
Leverage can include access to an audience, your skills, and capital. Trump views the strength of the American consumer as leverage, as Americans spend far more than any other country. Whether you're trying to win a trade war or grow your business, knowing these four components can help you land a good deal.
Read Next:
<ul>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Grant Cardone Explains The Art Of Negotiating: 'It Takes 4 Things To Make A Deal'

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">data becomes available</a>.
The update includes Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), which the U.S. Food and Drug Administration approved in October 2024 for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">risk of severe disease</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
The recommendation also includes GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy in adults aged 50-59 who are at increased risk <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853850/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-" rel="noreferrer noopener">for severe RSV disease</a>.
This expands on ACIP&#8217;s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older.
Arexvy is indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older and individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
According to the CDC, between 15,000 &#8211; 20,000 RSV-associated hospitalizations occur annually in U.S. adults <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44852139/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-5" rel="noreferrer noopener">aged 50 &#8211; 59 years</a>.
A systematic review of studies in the U.S. shows that RSV is estimated to cause 42,000 hospitalizations each year in adults aged 50-64 years old.
GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK&#8217;s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions compared to older adults aged 60 years and older where efficacy has been demonstrated after a single dose of GSK&#8217;s RSV vaccine.
The updated recommendation does not benefit Moderna Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mRNA-based RSV vaccine mRESVIA (mRNA-1345), which is currently approved for adults over 60 years.
William Blair notes Moderna shared Phase 3 data for mRNA-1345 in high-risk adults aged 18-59 at its 2024 R&amp;D Day event and has since submitted an application to the FDA for regulatory approval using a priority review voucher.&nbsp;The FDA <a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" rel="noreferrer noopener">has</a> accepted Moderna&#8217;s application and has assigned a PDUFA goal date of June 12, 2025.
Analyst Myles R. Minter highlights the Phase 3 trial of mRNA-1345 in over 1,000 high-risk individuals between ages 18 and 59. mRNA-1345 demonstrated non-inferior immunogenicity compared to adults age 60 or older for neutralizing antibodies against both RSV-A and RSV-B and a tolerable safety profile.
&#8220;If approved on time, we believe mRESVIA could be added to the updated age group recommendation during the scheduled June 25-26, 2025, ACIP meeting,&#8221; Minter said.
Price Action: PFE stock is up 1.07% 22.28, MRNA stock is down 2.30% at $24.62, and GSK stock is up 1.74% at $35.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars</a></li>
</ul>
Photo by pedro7merino via Shutterstock

Biotech

Large Cap

News

Health Care

General

MRNA

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares are ripping higher Thursday after rallying 56% on Wednesday following reports that Bill Ackman&#8217;s&nbsp;Pershing Square Capital Management built a sizable stake in the <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44853443/hertz-stock-accelerates-into-the-close-shares-continue-to-move-higher-after-hours-heres-why">rental car company</a>.
What Happened: Pershing Square revealed in a regulatory filing Wednesday that the firm purchased 12.71 million shares of Hertz as of Dec. 31, representing a stake of approximately 4.1%.
Late Wednesday, <a href="https://www.cnbc.com/2025/04/16/-hertz-surges-after-bill-ackman-takes-big-stake-in-the-rental-car-firm.html">CNBC's</a>&nbsp;Scott Wapner&nbsp;reported on "Closing Bell" that a person familiar with the matter said Pershing&#8217;s stake is actually significantly higher at 19.8%, making Ackman&#8217;s firm the company&#8217;s second-largest shareholder.
Wapner reported that Pershing Square received a confidential treatment provision from the U.S. Securities and Exchange Commission, allowing the firm to delay the filing beyond the normally required reporting period. 
&#8220;Which gave them the ability to accumulate substantially more shares since the end of December," Wapner said.
Hertz filed for <a href="https://www.benzinga.com/news/21/03/19944861/hertz-in-chapter-11-due-to-pandemic-will-emerge-with-new-owners-financing">Chapter 11 protection</a> during the COVID-19 pandemic. The company emerged from the restructuring in 2021 with a plan to shift its focus to electric vehicles, but losses mounted due to vehicle value declines. 
CNBC reported that Pershing is optimistic about a turnaround under new management. The source also reportedly said Pershing's bet is partially a tariff play since used cars aren't impacted by tariffs.
Hertz said in February that it was focused on &#8220;stabilizing the business&#8221; and implementing changes to &#8220;transform&#8221; the company.
Hertz shares are seeing a lot of attention on Thursday. The stock was the top trending ticker across multiple social sites at the time of writing. The company had a market cap of approximately $1.75 billion as of Wednesday&#8217;s close, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
HTZ Price Action: <a href="http://benzinga.com/quote/htz" target="_blank" rel="noreferrer noopener">Hertz Global shares</a> were up 40.3% at $8.01 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44863298/whats-going-on-with-avis-budget-group-car-stock">What&#8217;s Going On With Avis Budget Group (CAR) Stock?</a></li>
</ul>
Photo: ricochet64/Shutterstock.

Movers

Hertz Stock Is Racing Higher Thursday: What's Driving The Action?

BMO Capital Markets analyst Evan David Seigerman downgraded Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) from Outperform to Market Perform,<a target="_blank" href="https://www.benzinga.com/quote/NVO/analyst-ratings" rel="noreferrer noopener"> lowering the price forecast from $105 to $64.</a>
Per Seigerman, Novo Nordisk&#8217;s stock may underperform compared to peers in the cardiometabolic space, particularly Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44871681/lillys-diabetes-pill-clears-major-trial-analyst-points-to-global-potential" rel="noreferrer noopener">Lilly&#8217;s Diabetes Pill Clears Major Trial, Analyst Points To Global Potential</a>
The analyst highlights that Lilly&#8217;s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo Nordisk&#8217;s Ozempic and Wegovy.
Seigerman noted that although Novo Nordisk initially benefited from being first to market with semaglutide, that early lead is quickly diminishing.
Eli Lilly&#8217;s tirzepatide is rapidly capturing market share, and the analyst projects this momentum to continue.
The analyst pointed out that recent clinical comparisons have shown tirzepatide outperforming semaglutide, and this advantage is already reflected in U.S. script data.
According to Seigerman, tirzepatide&#8217;s continued growth to further slow the momentum of Novo Nordisk&#8217;s Wegovy and Ozempic.
In the near term, the analyst is doubtful that Novo Nordisk&#8217;s upcoming drug CagriSema will be able to effectively compete, citing disappointing results from the REDEFINE trial.
With additional drugs like orforglipron and retatrutide in Lilly&#8217;s pipeline, the competitive pressure on Novo Nordisk is likely to intensify going forward.
Additionally, upcoming data on orforglipron could introduce more competition and weigh on Novo Nordisk&#8217;s stock.
Overall, the analyst does not expect the company&#8217;s 2025 developments to be strong enough to reverse this trend or significantly boost its market position.
Price Action: Novo Nordisk shares are trading lower by 7.1% to $58.41 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44866751/forge-global-eyes-strategic-expansion-with-10m-accuidity-acquisition" target="_blank" rel="noreferrer noopener">Forge Global Eyes Strategic Expansion With $10 Million Accuidity Acquisition</a></li>
</ul>
Image: Shutterstock

Equities

Markets

Analyst Ratings

Trading Ideas

Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock

The U.S. Treasury&#8217;s cash balance sharply increased during <a href="https://www.benzinga.com/government/regulations/25/04/44803590/federal-tax-return-deadline-looms-what-to-know-about-extensions-payments-late-filings">2025&#8217;s tax season</a> as collections rose from the previous year&#8217;s season.
What Happened: The Treasury&#8217;s cash balance rose by $185 billion on Tuesday, the U.S. deadline to file tax returns for the previous year, <a href="https://www.bloomberg.com/news/articles/2025-04-17/tax-collections-boost-treasury-s-cash-pile-by-most-since-2022">according </a>to Bloomberg. This represents the largest one-day increase since 2022. On the whole, tax receipts are substantially higher than they were in 2024.
The department&#8217;s cash pile is now $600 billion, the highest tally since February. This is still substantially lower than the account&#8217;s balance through 2024.
The tax collection increase is linked to a surge in individual, non-withheld taxes paid electronically, according to Bloomberg.
Why it Matters: This influx gives the Treasury more flexibility to manage short-term funding needs, avoid disruptions such as debt ceiling standoffs and reduce reliance on borrowing. Politicians in Washington reluctantly <a href="https://www.benzinga.com/news/25/01/43072897/janet-yellen-warns-us-could-hit-debt-ceiling-on-tuesday-suspends-investments-in-2-government-employee-benefit-funds">raised the debt ceiling</a> earlier this year; a default could be catastrophic for the U.S. economy.
A higher cash balance also gives the Treasury more leverage in timing debt issuance, potentially reducing borrowing costs if rates remain volatile. It signals to markets that the government is on a stronger footing, which can help stabilize investor sentiment amid ongoing uncertainty about inflation, interest rates and the Federal Reserve's next moves.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a></li>
</ul>

Government

Economics

Federal Reserve

Tax Collections Tick Up As Treasury Ledgers Elevate Cash Baance

DA Davidson analyst Manuel Navas maintains Fulton Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULT#NASDAQ">FULT</a>) with a Neutral and lowers the price target from $20 to $17.

Price Target

FULT

DA Davidson Maintains Neutral on Fulton Financial, Lowers Price Target to $17

DA Davidson analyst Peter Winter maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Buy and lowers the price target from $54 to $49.

DA Davidson Maintains Buy on U.S. Bancorp, Lowers Price Target to $49

DA Davidson analyst Peter Heckmann maintains Donnelley Financial Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>) with a Buy and lowers the price target from $72 to $64.

DFIN

DA Davidson Maintains Buy on Donnelley Financial Solns, Lowers Price Target to $64

WIIM

BBWI

ETSY

FIVE

JEWL

LEVI

OLLI

ULTA

URBN

Shares of retail, apparel and e-commerce stocks are trading higher. Some stocks in the sector may be higher amid hopes of a US-China trade deal. Additionally, discount store stocks could be benefitting from broader economic concerns. E-commerce stocks may also be up up Chinese discount retailers Temu and Shein planning to increase prices.

Editor&rsquo;s note: This article was originally published in May 2024. Some time references have been updated as of April 2025 for clarity and context.
&ldquo;Imagine if it was never prohibited. <a href="https://www.benzinga.com/cannabis">Cannabis</a> would be a trillion-dollar industry that was ours,&rdquo; says <a href="https://elplanteo.com/dreka-gates/">Dreka Gates</a> in an exclusive interview, reflecting on the historical and social implications of cannabis prohibition and its disproportionate impact on Black and Brown communities in America and beyond. As an accomplished entrepreneur &ndash; and wife of rapper Kevin Gates, Dreka is carving out a significant space for herself in the wellness and cannabis industries, driven by a profound personal connection to plant medicine.
Dreka&#39;s journey with cannabis began in her teen years with a challenging first encounter. &quot;My first time smoking was an absolutely horrible experience,&quot; she admits. Paranoia and anxiety marked her initial attempt, but her curiosity pushed her to try again. This time, cannabis provided a sense of relaxation and openness that became central to her wellness routine. Today, Dreka uses cannabis to manage anxiety and incorporates other therapeutic plants and fungi into her daily regimen. &quot;I also microdose with psychedelic mushrooms for healing past traumas and functional mushrooms daily,&quot; she explains.
Her holistic approach to wellness is deeply rooted in personal experience and education. Dreka took a three-day crash course at Oaksterdam University in Oakland in 2016, which covered everything from seed to sale, business and growing aspects of cannabis. This foundation empowered her to enter the cannabis industry with confidence and expertise.
<h3>A Crop Harvested With Love</h3>
In 2021, a Michigan-based cannabis company offered Dreka a partnership, where she took on roles in marketing and research and development. This opportunity was a stepping stone to her solo venture, Love&#39;s Harvest, based in Mississippi.
<img alt="Dreka Gates" src="https://imageio.forbes.com/specials-images/imageserve/66467015fbaf8728f0e4ab30/Dreka-Gates/960x0.jpg?format=jpg&amp;width=1440" style="height:450px; width:296px" />
Dreka Gates. SHANNON LAURINEX
&quot;Love&#39;s Harvest is my love, my harvest,&quot; she says, describing her cannabis operation. Her vision for Love&#39;s Harvest is to create a space that educates and destigmatizes cannabis use, particularly in the conservative Bible Belt. &quot;I&#39;m still in the Bible Belt, and a lot of people still look at it like, &#39;Oh, that&#39;s dope, that&#39;s a drug,&#39;&quot; she explains.
However, she is confident in her ability to educate and transform these outdated views, showing that cannabis can be a powerful tool for wellness and healing. &quot;You can literally just plant a seed outside in your backyard and you don&#39;t have to do anything to it. It&#39;ll just grow and it&#39;ll just be there. How can this possibly be illegal?&quot; she adds.
<h3>Weed Wellness</h3>
The wellness market in the U.S. is booming,&nbsp;<a href="https://www.luxurytribune.com/en/the-wellness-industry-a-market-valued-at-1-5-trillion-dollars" rel="nofollow noopener noreferrer" target="_blank" title="https://www.luxurytribune.com/en/the-wellness-industry-a-market-valued-at-1-5-trillion-dollars">valued</a>&nbsp;at over $1.5 trillion and still projected to grow steadily each year. Similarly, the cannabis market is experiencing rapid expansion, with&nbsp;<a href="https://www.forbes.com/sites/irisdorbian/2021/06/18/legal-cannabis-market-projected-to-rack-up-43-billion-by-2025-says-new-study/?sh=557f6d8e36b4" target="_self" title="https://www.forbes.com/sites/irisdorbian/2021/06/18/legal-cannabis-market-projected-to-rack-up-43-billion-by-2025-says-new-study/?sh=557f6d8e36b4">estimates</a>&nbsp;suggesting it could reach $43 billion in 2025 &mdash; a milestone the industry is now approaching. Dreka&#39;s dual focus on wellness and cannabis positions her uniquely at the intersection of these lucrative industries. She has been developing a line of products that blend cannabis with other herbs and plants, including topicals, pills and edibles. &quot;Some people are so accustomed to taking pills,&quot; she notes, &quot;so we have those too.&quot;
<img alt="Dreka Gates" src="https://imageio.forbes.com/specials-images/imageserve/66466feb6f70c796d21d2f57/Dreka-Gates/960x0.jpg?format=jpg&amp;width=1440" style="height:416px; width:624px" />
Dreka Gates. SHANNON LAURINEX
Her efforts aim to make medication approachable and enjoyable. &quot;It&#39;s instilled in us that medication has to feel bad to be therapeutic,&quot; she reflects. Dreka challenges this notion by offering products that are both effective and pleasant to use. &quot;But aside from that, it has so many benefits recreationally and medicinally. For those people that just want to take the edge off after they get home from a long day&#39;s work or something, it&#39;s good for that.&quot; Her goal is to meet people where they are, providing options that suit different preferences and lifestyles.
Dreka&#39;s holistic approach to wellness extends beyond the physical products she offers. She is also passionate about creating experiences that foster healing and growth. She has hosted retreats and pop-up events designed to merge wellness and cannabis, offering participants a comprehensive approach to health that addresses mental, physical and spiritual needs. &quot;My intention is to create educational programs and retreats where people can experience what it&#39;s like for wellness and cannabis to be one,&quot; she says.
The wellness retreats feature a variety of activities, including yoga, meditation and educational workshops on the benefits of cannabis and other plant medicines. These events are part of her broader vision to destigmatize cannabis and integrate it into mainstream wellness practices. &quot;Cannabis is just another plant that has the ability to really heal and make us feel better,&quot; Dreka asserts.
<h3>&lsquo;Lock In On That Vision And Just Go For It&rsquo;</h3>
Dreka&#39;s dedication to wellness and cannabis isn&#39;t just about personal gain; it&#39;s about community empowerment and education. Her path took a significant turn when she and her husband, Kevin Gates, co-founded the Breadwinners Association. Initially a record label, the Breadwinners Association expanded its work into the lifestyle realm, creating a brand that resonated deeply with the Gates&rsquo; audience. &quot;It&#39;s all about building a solid foundation and creating an organic community,&quot; she says.
<img alt="Dreka Gates" src="https://imageio.forbes.com/specials-images/imageserve/664670a79db3fcef0cfedaac/Dreka-Gates/960x0.jpg?format=jpg&amp;width=1440" style="height:450px; width:297px" />
Dreka Gates. SHANNON LAURINEX
This philosophy seamlessly transitioned into her wellness and cannabis businesses. At Love&#39;s Harvest, Dreka aims to provide a sanctuary where people can learn about and experience the benefits of cannabis in a supportive environment. &quot;I want people to walk in and feel like they&#39;re being transported to a different place,&quot; she explains, discussing her dispensary. In fact, the store is a place reminiscent of Tulum, Mexico, a nod to where her healing journey began, she says.
Dreka&#39;s entrepreneurial journey is marked by a relentless pursuit of her vision, despite numerous challenges. She acknowledges the obstacles she has faced, particularly as a woman in a male-predominantly industry like entertainment is. Yet, her experience with cannabis has been different: &quot;Most of the people I interact with in the cannabis space are women,&quot; she notes, challenging the perception of cannabis as a male-dominated field. What&rsquo;s more, Dreka encourages other women to pursue their passions in the industry, emphasizing that they too can create their own space and make a significant impact.
Her background in the entertainment industry has equipped her with unique skills that she applies to her cannabis and wellness ventures. From booking gigs for Kevin at $250 to negotiating six-figure deals, Dreka has honed her business acumen and strategic thinking. These experiences have taught her the importance of risk-taking and staying true to one&#39;s vision. &quot;Once you have your vision, lock in on that vision and just go for it,&quot; she advises. &quot;Be creative and do what feels good to you.&quot;
<h3>A Mission To Destigmatize Cannabis</h3>
One of Dreka&#39;s key initiatives is developing a line of products that combine cannabis with other beneficial herbs and plants. &quot;We&#39;re doing an entire line,&quot; she says, emphasizing the variety of products she plans to introduce. These products are not only intended for recreational use but are also formulated to address specific health concerns, making them a versatile addition to the wellness market.
Dreka&#39;s commitment to education is a cornerstone of her business strategy. She understands that changing perceptions about cannabis requires more than just offering products; it involves educating the public about the plant&#39;s benefits and uses. Through Love&#39;s Harvest, she aims to provide a space where people can learn about cannabis in a supportive and informative environment. &quot;My intention is to destigmatize the use of cannabis and to make it not so taboo,&quot; she explains.
In addition to her product lines and educational efforts, Dreka is also focused on creating community-driven experiences. Her retreats and pop-up events offer participants an immersive experience that combines wellness practices with cannabis education. These events provide an opportunity for individuals to explore the benefits of cannabis in a holistic setting, fostering a deeper understanding and appreciation of the plant.
<img alt="Dreka Gates" src="https://imageio.forbes.com/specials-images/imageserve/664670c1091d57f90faf7f84/Dreka-Gates/960x0.jpg?format=jpg&amp;width=1440" style="height:416px; width:624px" />
Dreka Gates. SHANNON LAURINEX
Dreka&#39;s approach to business is deeply personal, drawing on her own experiences and passions. She sees herself as a healer at heart, a role that guides her work in both the wellness and cannabis industries. &quot;I&#39;m sharing tools for healing past traumas and achieving full-body wellness. I&#39;m working on sex and love certification, being a doula, and creating educational programs and retreats.&quot; This perspective is reflected in her plans for future ventures, which include expanding her reach and influence through collaborations and partnerships.
As cannabis rescheduling becomes more likely, Dreka remains optimistic about the future of the cannabis and wellness industries. She believes that as more people become educated about the benefits of cannabis, societal perceptions will continue to shift, leading to greater acceptance and integration of the plant into mainstream wellness practices. &quot;I&#39;m just here having fun and living out my purpose,&quot; she concludes, displaying the joy and fulfillment she finds in her work. &quot;Women should just go for it and create their own space in cannabis.&quot;
Follow me on&nbsp;<a href="https://www.twitter.com/javierhasse" rel="nofollow noopener noreferrer" target="_blank">Twitter</a>&nbsp;or&nbsp;<a href="https://www.linkedin.com/in/javierhasse/" rel="nofollow noopener noreferrer" target="_blank">LinkedIn</a>.&nbsp;Check out&nbsp;my&nbsp;<a href="https://elplanteo.com/" rel="nofollow noopener noreferrer" target="_blank">website</a>&nbsp;or&nbsp;some of my other work&nbsp;<a href="https://benzinga.com/cannabis" rel="nofollow noopener noreferrer" target="_blank">here</a>.&nbsp;
This article was originally published on <a href="https://www.forbes.com/sites/javierhasse/2024/05/17/dreka-gates-cannabis-would-be-a-trillion-dollar-industry-for-black-brown-communities-if-it-had-never-been-illegal/">Forbes</a> and appears here with permission.&nbsp;The article is from an external source. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.
Photo by&nbsp;Shannon Laurinex, courtesy of Dreka Gates.

Cannabis

Dreka Gates: 'Cannabis Would Be A Trillion-Dollar Industry For Black And Brown Communities—If It Hadn't Been Criminalized'

Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are <a target="_blank" href="https://www.benzinga.com/news" rel="noreferrer noopener">trading lower on Thursday</a>. The company&#8217;s joint venture with Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>), named Hidrogenii, officially launched operations at its new hydrogen liquefaction facility in St. Gabriel, Louisiana—one of the largest of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44860452/hidrogenii-a-plug-and-olin-joint-venture-commissions-15-ton-per-day-hydrogen-liquefaction-plant-in" rel="noreferrer noopener">its kind in North America.</a>
The plant, capable of liquefying up to 15 metric tons of hydrogen per day, will serve Plug&#8217;s material handling customers nationwide.
The move marks a significant step toward building a robust U.S.-based hydrogen supply chain and underscores Plug&#8217;s ongoing effort to scale its green energy production network, the company said in a press release.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44868280/us-listed-chinese-stocks-face-250-billion-forced-selling-risk-as-delisting-fears-emerge-what-investors-need-to-know" rel="noreferrer noopener">US-Listed Chinese Stocks Face $250 Billion Forced Selling Risk As Delisting Fears Emerge: What Investors Need To Know</a>
Hydrogen for the St. Gabriel plant will be produced by Olin and distributed via trailers under Plug&#8217;s spot pricing model.
With this addition, Plug&#8217;s total hydrogen production capacity now reaches 40 metric tons per day, including output from its existing Georgia and Tennessee facilities.
The company emphasized the cost and reliability benefits of sourcing domestically produced hydrogen, which reduces its reliance on external suppliers.
&#8220;This Louisiana plant, a milestone in expanding our U.S. hydrogen network, bolsters our financial position by leveraging a dependable, cost-effective hydrogen source,&#8221; said Andy Marsh, CEO of Plug Power.
He noted that this development helps strengthen the company&#8217;s operational foundation while supporting growth.
Ken Lane, President and CEO of Olin, described the joint venture as aligned with Olin&#8217;s strategic priorities. Lane called it &#8220;a value-first approach&#8221; that builds on core competencies through adjacent, capital-efficient projects.
Formed in 2022, Hidrogenii was created to develop and operate hydrogen infrastructure.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLUG stock has lost over 66% in the past year. Investors can gain exposure to the stock via&nbsp;Global X Hydrogen ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYDR#NASDAQ">HYDR</a>).
Price Action: PLUG shares are trading lower by 1.79% to $0.90 at last check on Thursday.
Read Now:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44862662/trump-pressures-fed-as-ecb-delivers-7th-straight-rate-cut" target="_blank" rel="noreferrer noopener">Trump Pressures Fed As ECB Delivers 7th Straight Rate Cut</a></li>
</ul>
Photo by T. Schneider via Shutterstock

HYDR

PLUG

What's Going On With Plug Power Stock On Thursday?

During an official Oval Office meeting with Italian Prime Minister Giorgia Meloni, President Donald Trump reignited his push against Federal Reserve Chair Jerome Powell, warning he could remove him if rate cuts don't come soon—just hours after another round of <a href="https://www.benzinga.com/government/regulations/25/04/44862662/trump-pressures-fed-as-ecb-delivers-7th-straight-rate-cut">policy easing from Europe.</a>
On Thursday, Trump and Meloni addressed reporters following bilateral talks on trade, China, Ukraine and broader transatlantic relations. The Italian leader praised her host's role in global affairs, saying: "The goal for me is to make the West great again."
Yet, Trump swiftly redirected the focus toward domestic monetary policy, using the moment to sharply criticize Powell.
<h3 class="wp-block-heading">&#8216;Oh, He'll Leave&#8217;</h3>
Trump accused the Fed chair of playing politics and holding rates unnecessarily high despite disinflationary signals across major sectors.
"He's too late. Always too late. A little slow. And I'm not happy with him," Trump said, adding, "Oh, if I want him out, he'll be out of there real fast. Believe me." He continued: "He'll be out of there if I ask him."
Powell's term as Fed chair runs through May 2026, and he has previously defended the central bank's independence by noting that his position is protected by statute. A Federal Reserve chair can only be removed for cause, which has historically been interpreted as misconduct or incapacity—not policy disagreements.
Trump pointed directly to the ECB's aggressive monetary easing as a model the Fed should follow. 
"In Europe, they've reduced [rates] seven times… but our guy wants to play cute," he said, warning that keeping U.S. rates higher puts the economy at a disadvantage.
The U.S. Dollar Index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – was up 0.2% on Thursday, yet it has fallen by more than 10% since Trump&#8217;s inauguration in January. 
<h3 class="wp-block-heading">Inflation Is Essentially Gone, Trump Says</h3>
The president claimed that inflation is no longer a concern, arguing that falling oil, grocery and egg prices show clear evidence of relief. "We essentially have no inflation. It's hard to have inflation when oil goes down," he said.
Trump insisted the Fed is the only institution holding back the economy, saying, "Interest rates should be down now… they're not very smart. The Federal Reserve is playing politics."
"We're essentially being played by our own central bank," he added. 
As Trump left the podium Thursday, he summed up his stance plainly: "The Fed owes it to the American people to get interest rates down. That's the only thing he's good for."
<h3 class="wp-block-heading">Meloni Meeting Covers Trade, China, Ukraine</h3>
Meloni hinted at a deeper NATO commitment, signaling Italy's increasing willingness to meet defense spending targets. 
The two also briefly discussed China, with Trump noting, "We're doing very well with negotiations… everyone wants to make a deal. If they don't, we'll make it for them."
A U.S.-Ukraine mineral deal is expected to be signed next Thursday, as part of efforts to deepen Western investment and counter Russian influence.
Trump reiterated his skepticism toward Ukrainian President Volodymyr Zelenskyy, stating, "I'm not a big fan of Zelenskyy. He hasn't done a good job."
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Photo: noamgalai/Shutterstock

Macro Economic Events

Eurozone

Politics

Econ #s

PowerShares DB US Dollar Index Bullish Fund

'He'll Be Out... If I Ask Him': Can Trump's Threat To Oust Powell Shake The Fed?

On Thursday, Keybanc analyst Steve Barger downgraded Amkor Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) from <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noreferrer noopener">Overweight to Sector Weight</a>.
The rerating reflects reduced visibility into demand for mobile phones, automobiles, and consumer products, which stems from fluctuating trade policy.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/04/44851295/asml-cfo-incorporates-tariff-impact-in-outlook-reveals-strong-demand-for-advanced-euv-and-high-na-systems" target="_blank" rel="noreferrer noopener">ASML CFO Incorporates Tariff Impact In Outlook, Reveals Strong Demand For Advanced EUV And High NA Systems</a>
Barger noted that it could exacerbate the expected gross margin pressure in the first half of 2025 due to a temporary socket loss in its Mobile end market and expressed concern about Amkor&#8217;s inherently lower-visibility but relatively high-capex business model.
The analyst noted that shares will likely remain under pressure until major end markets like Automotive and Mobile show signs of stabilization and growth.
Amkor automotive sales generally track the major automotive semiconductor companies, and while consensus estimates indicate a return to growth in the second half of 2025, Barger noted that company commentary combined with volatile global trade rhetoric suggests a cautious approach to shares in the near term.
In a broader upcycle scenario, the analyst noted Amkor should exhibit substantial operating leverage on higher factory utilization, but that will require recovery and growth across high-volume end markets for that to happen.
As one of a handful of outsourced manufacturing companies able to process 2.5D advanced packages with acceptable yield and throughput, Barger noted Amkor will continue to focus on high-performance computing as a margin-accretive and higher-growth vector.
The analyst noted volumes are still too small to drive consolidated company outperformance, absent participation from traditional end markets. Amkor could remain a &#8220;second choice&#8221; for leading-edge chip companies behind the technology leader, Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Barger lowered his estimates to reflect heightened uncertainty in global trade and end demand. The analyst&#8217;s 2025 estimate goes to $1.40 from $1.48 (consensus $1.41), reflecting a -2% growth rate at a 6% decremental margin. His 2026 estimate goes to $1.91 from $2.04 (consensus $1.96), reflecting 9% growth on a 34% incremental margin.
Given the recent share price action, Barger acknowledged that his downgrade was reactive. Still, when he noted the market position and the potential impact of reduced demand across mobile phones, autos, and other consumer products, he had less confidence in predicting near-term outcomes for Amkor than for some other names he covered.
For now, Barger noted that the demand for AI-related devices and investments in leading-edge roadmaps should remain resilient, and he is more positive about names exposed to upgrade cycles or where channel inventory has been reduced, like memory. Looking forward, when this macro angst passes and improving cycle dynamics become more apparent, the analyst could be quick to reverse course, but for now, he noted more positive outlooks for Overweight-rated Applied Materials, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), Lam Research Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Advanced Energy Industries, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) and MKS Instruments, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>).
Price Action: AMKR stock is down 0.33% at $16.10 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44841545/applied-materials-lam-research-kla-drop-amid-fresh-trade-war-fears-revenue-risk" target="_blank" rel="noreferrer noopener">Applied Materials, Lam Research, KLA Drop Amid Fresh Trade War Fears, Revenue Risk</a></li>
</ul>
Image: Shutterstock

Downgrades

AEIS

AMAT

AMKR

LRCX

MKSI

Amkor Stock Under Pressure: Analyst Cuts Rating Due To Trade Policy Concerns, Slowing End Market Growth

Goldman Sachs analyst John Mackay shared views on Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), which reported first-quarter earnings <a href="https://www.benzinga.com/news/earnings/25/04/44852989/kinder-morgan-q1-earnings-revenue-beat-eps-miss-forward-guidance-our-company-can-be-a-safe-haven-during-the-storm" target="_blank" rel="noreferrer noopener">on Wednesday after market close</a>.
The energy infrastructure company reported revenue of $4.24 billion, missing the consensus estimate of $4.08 billion, and adjusted quarterly earnings of 34 cents per share, which fell short of analyst estimates of <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">35 cents per share</a>.
Kinder Morgan expects full-year 2025 earnings of $1.27 per share versus&nbsp;Benzinga Pro&nbsp;estimates of $1.28 per share and net income attributable to the company <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to be up 8% compared to 2024</a>.
Mackay writes that weaker-than-expected product performance, largely due to maintenance on a condensate splitter, contributed to the earnings shortfall, though the gas business remains healthy.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44541993/kinder-morgan-set-for-q1-growth-amid-rising-lng-demand-says-analyst" rel="noreferrer noopener">Goldman Sachs Forecasts High Gas Prices And LNG Demand Drive Kinder Morgan&#8217;s Revenue</a>
Management expressed confidence in achieving its full-year 2025 EBITDA target of approximately $8.35 billion, even in a less favorable economic environment (vs. GS estimates: $8.32 billion; consensus: $8.37 billion), the analyst notes.
Overall, the analyst believes that the reaffirmed EBITDA outlook, growing backlog, and strong demand signals paint a constructive picture.
Mackay says that for the rest of the year, key areas of focus include how the broader economic environment aligns with what was originally factored into company guidance, especially given recent pricing trends that show strength. At the same time, future commodity prices and volumes could soften.
Attention will also be on upcoming announcements for both smaller and larger-scale projects, with interest in how these initiatives progress in the near term, adds the analyst.
The analyst reiterated a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/KMI/analyst-ratings" rel="noreferrer noopener">with a price target of $31</a>.
Investors can gain exposure to the stock through the Global X MLP &amp; Energy Infrastructure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLPX#NYSE">MLPX</a>) and the Ultimus Managers Trust Westwood Salient Enhanced Midstream Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDST#NYSE">MDST</a>).
Price Action: KMI shares are up 1.86% at $27.45 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43540757/oil-prices-trim-losses-as-department-of-treasury-issues-sanctions-on-irans-crude-shipments-to-china" target="_blank" rel="noreferrer noopener">Oil Prices Trim Losses As Department Of Treasury Issues Sanctions On Iran&#8217;s Crude Shipments To China</a></li>
</ul>
Photo: Shutterstock

Reiteration

MDST

MLPX

Kinder Morgan's Backlog And Demand Trends Keep 2025 EBITDA On Track, Says Goldman

LXEH

Lixiang Education Holding Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.7%

UBS analyst Peter Grom maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Neutral and lowers the price target from $43 to $31.

YETI

UBS Maintains Neutral on YETI Holdings, Lowers Price Target to $31

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $629.44, with a high estimate of $715.00 and a low estimate of $475.00. Experiencing a 2.53% decline, the current average is now lower than the previous average price target of $645.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916464_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Thermo Fisher Scientific by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $580.00&#x7C;$680.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $475.00&#x7C;$620.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $570.00&#x7C;$650.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $650.00&#x7C;$605.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Raises &#x7C;Outperform &#x7C; $667.00&#x7C;$650.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $650.00&#x7C;$600.00 &#x7C; 
&#x7C;Dan Leonard &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $715.00&#x7C;$700.00 &#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $680.00&#x7C;$660.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $678.00&#x7C;$647.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Thermo Fisher Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Thermo Fisher Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Thermo Fisher Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>All You Need to Know About Thermo Fisher Scientific</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
<h3>Understanding the Numbers: Thermo Fisher Scientific's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3M period, Thermo Fisher Scientific showcased positive performance, achieving a revenue growth rate of 4.68% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Thermo Fisher Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA stands out, surpassing industry averages. With an impressive ROA of 1.85%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Thermo Fisher Scientific: Insights From 9 Financial Analysts

Financial giants have made a conspicuous bullish move on JD.com. Our analysis of options history for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) revealed 33 unusual trades.
Delving into the details, we found 60% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 17 were puts, with a value of $1,703,637, and 16 were calls, valued at $1,066,568.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $40.0 for JD.com during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for JD.com's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JD.com's whale trades within a strike price range from $30.0 to $40.0 in the last 30 days. 
<h3>JD.com Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916463_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.37</td>
<td>$37.50</td>
<td>$681.7K</td>
<td>16.6K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.39</td>
<td>$1.35</td>
<td>$1.38</td>
<td>$31.00</td>
<td>$344.9K</td>
<td>1.4K</td>
<td>2.5K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.85</td>
<td>$8.55</td>
<td>$8.82</td>
<td>$35.00</td>
<td>$131.9K</td>
<td>580</td>
<td>205</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.49</td>
<td>$30.00</td>
<td>$129.7K</td>
<td>3.3K</td>
<td>518</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$6.5</td>
<td>$6.45</td>
<td>$6.48</td>
<td>$30.00</td>
<td>$116.6K</td>
<td>3.3K</td>
<td>180</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
In light of the recent options history for JD.com, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of JD.com</h3>
<ul>
<li>Currently trading with a volume of 9,543,647, the JD's price is down by -0.76%, now at $35.06. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 28 days.</li>
</ul>
<h3>Expert Opinions on JD.com</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $48.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on JD.com with a target price of $48. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JD.com options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On JD.com

Deep-pocketed investors have adopted a bullish approach towards Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 73 extraordinary options activities for Advanced Micro Devices. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 57% leaning bullish and 30% bearish. Among these notable options, 45 are puts, totaling $3,121,011, and 28 are calls, amounting to $1,915,075.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $60.0 to $260.0 for Advanced Micro Devices during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Advanced Micro Devices's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Advanced Micro Devices's whale activity within a strike price range from $60.0 to $260.0 in the last 30 days. 
<h3>Advanced Micro Devices Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744916458_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/25/25</td>
<td>$2.46</td>
<td>$2.43</td>
<td>$2.45</td>
<td>$87.00</td>
<td>$502.2K</td>
<td>1.1K</td>
<td>4.0K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/17/27</td>
<td>$29.6</td>
<td>$29.25</td>
<td>$29.4</td>
<td>$100.00</td>
<td>$441.0K</td>
<td>824</td>
<td>167</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$10.5</td>
<td>$10.4</td>
<td>$10.45</td>
<td>$85.00</td>
<td>$209.0K</td>
<td>11.1K</td>
<td>955</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$110.00</td>
<td>$155.4K</td>
<td>2.6K</td>
<td>1.2K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$4.85</td>
<td>$70.00</td>
<td>$130.4K</td>
<td>5.8K</td>
<td>413</td>
</tr>
</tbody>
</table>

<h3>About Advanced Micro Devices</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
After a thorough review of the options trading surrounding Advanced Micro Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Advanced Micro Devices Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 25,325,341, with AMD's price down by -0.68%, positioned at $87.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
<h3>What The Experts Say On Advanced Micro Devices</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $124.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Advanced Micro Devices, which currently sits at a price target of $100. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $120. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Advanced Micro Devices with a target price of $120. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Advanced Micro Devices with a target price of $126. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Advanced Micro Devices, targeting a price of $155. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Advanced Micro Devices options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Advanced Micro Devices's Options Frenzy: What You Need to Know

Across the recent three months, 5 analysts have shared their insights on Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $130.6, a high estimate of $133.00, and a low estimate of $124.00. This current average has increased by 1.87% from the previous average price target of $128.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1744916456_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Itron is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $133.00&#x7C;$133.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $133.00&#x7C;$135.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $124.00&#x7C;$119.00 &#x7C; 
&#x7C;Austin Moeller &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $132.00&#x7C;$130.00 &#x7C; 
&#x7C;Noah Kaye &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $131.00&#x7C;$124.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Itron. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Itron compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Itron's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Itron's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITRI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Itron analyst ratings.</a>
<h2>Discovering Itron: A Closer Look</h2>
Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.
<h3>Unraveling the Financial Story of Itron</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, Itron showcased positive performance, achieving a revenue growth rate of 6.18% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Itron's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.48%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Itron's ROE excels beyond industry benchmarks, reaching 4.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.72%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.91, Itron faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Procore Technologies

空売り

Procore Technologies (NYSE:PCOR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル